Talk:Management of tuberculosis: Difference between revisions

Content deleted Content added

Inline

Revision as of 07:22, 17 April 2007

Removed: "New and Innovative Possible treatment

Tuberculosis remains such a huge health problem and one of the greatest threats to world security and health. We must look for new ways to treat it. In my opinion, DOTS, just doesn't seem to be working. Koch described the pathophysiology over 100 years ago in Kiel, but still one third of the world is infected. So we have developed an approach using Inhalational Phytochemcials(KielMix) which may be the answer and the first results are described here. Other researchers are adopting the same approach. This approach may also allow mass treatment of TB victims as in Russian prisons. (E Sherry, S Sivananthan, PH Warnke et al. Inhalational phytochemicals as possible treatment for pulmonary tuberculosis: two case reports. Am J Infect Control. 2004 Oct;32(6):369-70). " --SpacemanAfrica 05:39, 29 January 2006 (UTC)[reply]

Neck Abscess

I have undergone surgery of (Lymph left side) neck abscess (6 to 8 cm containing thick pus) on 17th July 2006. Under Regular medicine (1cap+3tab). I am getting one more abscess (2 cm now) next to the the last one which is removed. I am unable to understand why even after having regular medicine i am getting the abscess second time.. Infection caused by Mycobacterium tuberculosis as per various tests. Please let me know anything to stop the growth of mass..Help me out..

We don't give medical advice on wikipedia. If you don't feel confident with your current doctor's diagnosis and/or treatment, I recommend you seek a second opinion Nil Einne 23:27, 29 September 2006 (UTC)[reply]

Vitamin D and tuberculosis

Where should this paragraph go? Does it belong in tuberculosis treatment or in vitamin D?

Vitamin D supplementation appears to have a beneficial effect on the treatment of tuberculosis, although the mechanism by which this happens is not entirely clear. In mice, the mechanism appears to be up-regulation of nitric oxide-mediated killing,^[1] but this appears not to be the case in humans. Instead, in humans, vitamin D-mediated killing appears to happen via an antimicrobial peptide called cathelicidin.^[2] Indeed, reduced levels of vitamin D may explain the increased susceptibility of African-Americans to tuberculosis,^[2] and may also explain why phototherapy is effective for lupus vulgaris (tuberculosis of the skin),^[3] a finding which won Niels Finsen the Nobel Prize in 1903, because skin exposed to sunlight naturally produces more vitamin D.

Right, I've created a nutrition section and pasted this into a specific subsection on vitamin D.

References

^ Rockett KA, Brookes R, Udalova I; et al. (1998). "1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line". Infect Immunity. 66 (11): 5314–21. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
^ ^a ^b Liu PT, Stenger S, Li H; et al. (2006). "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response". Science. 311: 1770–3. PMID 16497887. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
^ Finsen NR. (1986). Om anvendelse i medicinen af koncentrerede kemiske lysstraaler. Copenhagen, Denmark: Gyldendalske Boghandels Forlag.

Deviations from the standard regimen

I have removed the following paragraph because the information is already contained in the section on extra-pulmonary TB.--Gak 14:55, 27 November 2006 (UTC)[reply]

The current regimen has been validated for adults with pulmonary TB but is also used to treat TB in the rest of the body (except infection of the brain or spinal cord). The US recommendation is 2HRZ/7HR for extra-pulmonary TB, but this recommendation is based on slim evidence and is not supported by the WHO. The only published evidence for 2HRZ/7HR is for TB osteomyelitis in weight-bearing bones.

CDR-TB

It should be noted that the first case of completely drug resistant tuberculosis (CDR-TB) was discovered in February 2007 in Italy. As its name suggests, it is resistant to every antibiotic known today, and the justified concern is that, as the head of TB at WHO says, "we are as helpless against completely drug-resistant TB as we were in the 19th century, before antibiotics." (New Scientist, 24 March 2007)

[1] Rockett KA, Brookes R, Udalova I; et al. (1998). "1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line". Infect Immunity. 66 (11): 5314–21. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

[Liu2006-2] Liu PT, Stenger S, Li H; et al. (2006). "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response". Science. 311: 1770–3. PMID 16497887. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

[3] Finsen NR. (1986). Om anvendelse i medicinen af koncentrerede kemiske lysstraaler. Copenhagen, Denmark: Gyldendalske Boghandels Forlag.

[1]

[2]

[3]

@@ Line 22: / Line 22: @@
 :The current regimen has been validated for adults with pulmonary TB but is also used to treat TB in the rest of the body (except infection of the brain or spinal cord). The US recommendation is 2HRZ/7HR for extra-pulmonary TB, but this recommendation is based on slim evidence and is not supported by the [[World Health Organisation|WHO]]. The only published evidence for 2HRZ/7HR is for TB osteomyelitis in weight-bearing bones.
+== CDR-TB ==
+It should be noted that the first case of completely drug resistant tuberculosis (CDR-TB) was discovered in February 2007 in Italy.  As its name suggests, it is resistant to every antibiotic known today, and the justified concern is that, as the head of TB at WHO says, "we are as helpless against completely drug-resistant TB as we were in the 19th century, before antibiotics." (New Scientist, 24 March 2007)